Table 2.
Meta-analysis for studies included in the analysis.
| Outcomes | Number of studies | Number of estimates | Pooled OR (95 % CI), I2 statistics (%), P-value for the heterogeneity Q test | Model used |
|---|---|---|---|---|
| COVID-19 infection | 3 | 4 | 0.99 (0.95–1.04); I2 = 0%, P = 0.504 | Random effects |
| ACEI | 3 | 3 | 0.98 (0.92–1.04); I2 = 0%, P = 0.542 | Random effects |
| ARB | 3 | 3 | 1.01 (0.95–1.07); I2 = 8.9%, P = 0.334 | Random effects |
| COVID-19 Mortality | 8 | 9 | 0.73 (0.5–1.07); I2 = 70.7%, P = 0.11 | Random effects |
| Type of data | Random effects | |||
| Unadjusted | 4 | 4 | 0.91 (0.51–1.61); I2 = 33.4%, P = 0.212 | Random effects |
| Adjusted | 4 | 5 | 0.66 (0.38–1.12); I2 = 82.2%, P < 0.001 | Random effects |
| Study location | Random effects | |||
| China | 5 | 5 | 0.65 (0.46−0.91); I2 = 0%, P = 0.529 | Random effects |
| Other countries | 3 | 4 | 0.88 (0.48–1.62); I2 = 86.1%, P < 0.001 | Random effects |
| Patient with indication | 6 | 7 | 0.62 (0.38–1.02); I2 = 74.8%, P = 0.001 | Random effects |
| ACEI/ARB vs non-ACEI/ARB antihypertensive drug | 4 | 4 | 0.48 (0.29−0.81); I2 = 0%, P = 0.3796 | Random effects |
| COVID-19 Severity | 7 | 8 | 0.98 (0.87–1.09); I2 = 42.8%, P = 0.093 | Random effects |
| Patient with indication | 5 | 6 | 0.95 (0.83–1.1); I2 = 57.6%, P = 0.038 | Random effects |